Status:
COMPLETED
Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone
Lead Sponsor:
Bial - Portela C S.A.
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days o...
Detailed Description
Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days o...
Eligibility Criteria
Inclusion
- A signed and dated informed consent form (ICF) before any study-specific screening procedure was performed,
- Male or female subjects aged 18 to 45 years, inclusive,
- Body mass index (BMI) between 19 and 30 kg/m2,
- Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead electrocardiogram (ECG),
- Negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies and anti-human immunodeficiency virus (HIV) antibodies at screening,
- Clinical laboratory test results clinically acceptable at screening and on D-1 of each treatment period,
- Negative screen for alcohol and drugs of abuse at screening and on D-1 of each treatment period,
- Non-smokers or ex-smokers for at least 3 months,
- Volunteer able to participate, and willing to give written informed consent and comply with the study restrictions,
- If female:
- Was not of childbearing potential by reason of surgery or, if of childbearing potential, uses an effective non-hormonal method of contraception (intrauterine device or intrauterine system; condom or occlusive cap \[diaphragm or cervical or vault caps\] with spermicidal foam or gel or film or cream or suppository; true abstinence; or vasectomized male partner, provided that he was the sole partner of that subject) for the entire duration of the study,
- Negative serum pregnancy test at screening and a negative urine pregnancy test on D-1 of each treatment period.
Exclusion
- Any clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders, or had a clinically relevant surgical history,
- Any clinically relevant abnormality in the coagulation tests,
- Any clinically relevant abnormality in the liver function tests,
- History of relevant atopy or drug hypersensitivity,
- History of alcoholism and/or drug abuse,
- Current consumption of more than 14 units of alcohol per week \[1 unit of alcohol = 280 mL beer (3-4°) = 100 mL wine (10-12°) = 30 mL spirits (40°)\],
- Any significant infection or known inflammatory process on screening or admission to each treatment period,
- Any acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea, heartburn) at the time of screening or admission to each treatment period,
- Use of medicines within 2 weeks of admission to first period that could affect the subject's safety or other study assessments, in the investigator's opinion,
- Previously received opicapone,
- Involvement in other clinical trials of any type within 90 days prior to screening,
- Participation in more than 2 clinical trials within the 12 months prior to screening,
- Blood donation or received any blood transfusion or any blood products within the 3 months prior to screening,
- Vegetarian, vegan or had medical dietary restrictions,
- Subject not able to communicate reliably with the investigator,
- Subjects who were unlikely to co-operate with the requirements of the study,
- Subjects who were unwilling or unable to give written informed consent,
- If female:
- Pregnant or breast-feeding,
- If of childbearing potential, a positive serum pregnancy test,
- Volunteer who did not use an accepted effective contraceptive method or used oral contraceptives,
Key Trial Info
Start Date :
February 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT02305316
Start Date
February 1 2014
End Date
March 1 2014
Last Update
August 21 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.